Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)

التفاصيل البيبلوغرافية
العنوان:	Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
المؤلفون:	Blauvelt, A, Ladizinski, B, Prajapati, VH, Laquer, V, Fischer, A, Eisman, S, Hu, XF, Wu, TS, Calimlim, BM, Kaplan, B, Liu, YY, Teixeira, HD, Liu, JH, Eyerich, K
المصدر:	Journal of the American Academy of Dermatology. 89(3):478-485
مصطلحات موضوعية:	Medicin och hälsovetenskap
URL الوصول:	http://kipublications.ki.se/Default.aspx?queryparsed=id:153898016
قاعدة البيانات:	SwePub

الوصف
تدمد:	10976787
DOI:	10.1016/j.jaad.2023.05.033